Relapsed Chronic Lymphocytic Leukemia (CLL) is an indication for drug development with over 130 pipeline drugs currently active. According to GlobalData, preregistered drugs for Relapsed Chronic Lymphocytic Leukemia (CLL) have a 71.43% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Relapsed Chronic Lymphocytic Leukemia (CLL) compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Relapsed Chronic Lymphocytic Leukemia (CLL) overview

Relapsed Chronic Lymphocytic Leukemia (CLL) refers to the return of the disease after a period of initial response to treatment. CLL is a type of cancer that affects the blood and bone marrow, characterized by the overproduction of abnormal lymphocytes. While initial treatments like chemotherapy or immunotherapy may lead to remission, CLL can sometimes recur. The management of relapsed CLL depends on various factors, including the duration of remission, previous treatments, and the individual’s overall health. Treatment options may include different medications, targeted therapies, or stem cell transplantation. The goal is to control the disease, manage symptoms, and improve the patient’s quality of life.

For a complete picture of PTSR and LoA scores for drugs in Relapsed Chronic Lymphocytic Leukemia (CLL), buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.